Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 5/20 | 0.31 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110240 | 0.87 | HTR2C (0.38) | ARHTR2CHTR2AGRIN2B | |
| SCHEMBL24110244 | 0.85 | GRM2 (0.33) | NR3C1PGRNR3C2HTR2CHTR2A | |
| SCHEMBL24110260 | 0.82 | HTR2C (0.37) | HTR2CHTR2AGRIN2B | |
| SCHEMBL25818077 | 0.82 | HTR2A (0.35) | NR3C1PGRNR3C2ARHTR2C | |
| SCHEMBL24110313 | 0.82 | NR3C1 (0.36) | NR3C1PGRNR3C2HTR2C | |
| SCHEMBL24110256 | 0.80 | NR3C1 (0.35) | NR3C1PGRNR3C2HTR2C | |
| SCHEMBL25818087 | 0.79 | NR3C1 (0.35) | NR3C1PGRNR3C2ARHTR2C | |
| SCHEMBL24109773 | 0.79 | HTR2C (0.51) | NR3C1PGRNR3C2HTR2CHTR2A | |
| SCHEMBL24109775 | 0.78 | HTR2C (0.52) | NR3C1PGRNR3C2ARHTR2C | |
| SCHEMBL24110292 | 0.77 | HTR2A (0.31) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | NR3C1 1240/4885PGR 1797/4885NR3C2 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.